Publications

If you would like to request a PDF for any of the below Research in Addiction Medicine Scholars (RAMS) published papers, please contact Jules Canfield, Program Manager, at jules.canfield@bmc.org

2020

Bach P, Hayashi K, Milloy MJ, Nosova E, Kerr T, Wood E, Fairbairn N. Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: A gender-based analysis. Drug Alcohol Rev. 2020. [Online ahead of print.]

Kimmel S, Bach P, Walley AY. Comparison of treatment options for refractory opioid use disorder in the United States and Canada: a narrative review. J Gen Intern Med. 2020;35(8):2418-2426. 

Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?. Subst Abus. 2020;41(1):110-120. 

2019

Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019;14(1):30. PMCID: PMC6717996

Bozinoff N, Luo L, Dong H, Krüsi A, DeBeck K. Street-involved youth engaged in sex work at increased risk of syringe sharing. AIDS Care. 2019; 31(1):69-76. PMCID: PMC6250570

Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone matters: What the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019; 10.1007/s11606-018-4801-3. PMID: 30729416 

Dean A, Kimmel S. Free trade and opioid overdose death in the United States. SSM Popul Health. 2019;8:100409. PMCID: PMC6606896

Manhapra A, Chakraborty A, Arias AJ. Topiramate pharmacotherapy for alcohol use disorder and other addictions: A narrative review. J Addict Med. 2019;13(1):7-22.

Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019;14(1):46. PMCID: PMC6921403

Vaezazizi LM, Campbell ANC, Pavlicova M, Hu MC, Nunes EV. Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders.J Subst Abuse Treat. 2019;105:64-70. 

2018

Bagley SM, Cheng DM, Winter M, Alford DP, LaBelle C, Walley AY, Samet JH. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests. Drug Alcohol Depend. 2018; 192:245-249. PMCID: PMC6291245

Bone CW, Goodfellow AM, Vahidi M, Gelberg L. Prevalence of sexual violence and its association with depression among male and female patients with risky drug use in urban federally qualified health centers. J Urban Health. 2018; 95(1): 111-115. PMCID: PMC5862699

Bozinoff N, Anderson BJ, Bailey GL, Stein MD. Correlates of stigma severity among persons seeking opioid detoxification. J Addict Med. 2018; 12(1):19-23. PMCID: PMC5786480

Chang DC, Klimas J, Wood E, Fairbairn N. A case of opioid overdose and subsequent death after medically supervised withdrawal: The problematic role of rapid tapers for opioid use disorder. 2018; 12(1):80-83. PMCID: PMC5786466

Jun JH, Fairbairn N. Integrating injectable opioid agonist treatment into a drug treatment court program: A case study. Subst Abus. 2018; 39(4): 493-496. PMCID: PMC6750900

Klimas J, Dong H, Fairbairn N, Socías E, Barrios R, Wood E, Kerr T, Montaner J, Milloy MJ. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting. Addict Sci Clin Pract. 2018; 13(1):3. PMCID: PMC5812056

Lundsberg LS, Peglow S, Qasba N, Yonkers KA, Gariepy AM. Is preconception substance use associated with unplanned or poorly timed pregnancy?. J Addict Med. 2018; 12(4): 321-328. PMCID: PMC6066412

Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-Year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776. 

Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary. Subst Abus. 2018;39(2):152-161. doi:10.1080/08897077.2017.1381663

Peglow SL, Binswanger IA. Preventing opioid overdose in the clinic and hospital: Analgesia and opioid antagonists. Med Clin North Am. 2018; 102(4):621-634. PMCID: PMC6029888

Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend. 2018; 189:166-171. PMCID: PMC 6139651

2017

Bozinoff N, Small W, Long C, DeBeck K, Fast D. Still “at risk”: An examination of how street-involved young people understand, experience, and engage with “harm reduction” in Vancouver’s inner city. Int J Drug Policy. 2017; 45:33-39. PMCID: PMC5576444

Bozinoff N, Wood E, Dong H, Richardson L, Kerr T, DeBeck K. Syringe sharing among a prospective cohort of street-involved youth: Implications for needle distribution programs. AIDS Behav. 2017; 21(9):2717-2725. PMCID: PMC5640474

Fairbairn N, Wood E, Dobrer S, Dong H, Kerr T, Debeck K. The relationship between hazardous alcohol use and violence among street-involved youth. Am J Addict. 2017; 26(8):852-858. PMCID: PMC5730057

Hui D, Weinstein ZM, Cheng DM, Quinn E, Kim H, Labelle C, Samet JH. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine. J Subst Abuse Treat. 2017; 79:12-19. PMCID: PMC5522736

Lévesque A, Campbell AN, Pavlicova M, Hu MC, Walker R, McClure EA, Ghitza UE, Bailey G, Stitzer M, Nunes EV. Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav. 2017; 65:74-80. PMCID: PMC5483182

Lin LA, Bohnert ASB, Jannausch M, Goesling J, Ilgen MA. Use of non-pharmacological strategies for pain relief in addiction treatment patients with chronic pain. Am J Addict. 2017; 26(6):564-567. PMCID: PMC5576866

Manhapra A, Rosenheck R. Tobacco use disorder among patients with smoking-related chronic medical disease: Association with comorbid substance use disorders. J Addict Med. 2017; 11(4):293-299. PMCID: PMC 5537028

Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, Samet JH, Saitz R. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017; 29(9):1129-1136. PMCID: PMC5543330

Weinstein ZM, Cheng DM, Quinn E, Hui D, Kim H, Gryczynski G, Samet JH. Psychoactive medications and disengagement from office based opioid treatment (OBOT) with buprenorphine. Drug Alcohol Depend. 2017; 170:9-16. PMCID: PMC5183557

Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in Office Base Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017; 74:65-70. PMCID: PMC5312773

2016

Fairbairn NS, Walley AY, Cheng DM, Quinn E, Bridden C, Chaisson C, Blokhina E, Lioznov D, Krupitsky E, Raj A, Samet JH. Mortality in HIV-infected alcohol and drug users in St.Petersburg, Russia. PLoS One. 2017; 11(11):e0166539. PMCID: PMC5127495

Lévesque A, Roy É, Jutras-Aswad D, Zang G, Artenie AA, Bruneau J. Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. Addict Behav. 2016; 62:54-9. PMID: 27318949

Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016; 160:82-9. PMCID: PMC4767635

Mortazavi BJ, Downing NS, Bucholz EM, Dharmarajan K, Mahapra A, Li SX, Negahban SN, Krumholz HM. Analysis of machine learning techniques for heart failure readmissions. Circ Cardiovasc Qual Outcomes. 2016; 9(6):629-640. PMCID: PMC5459389

Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL. Reasons for benzodiazepine use among persons seeking opioid detoxification. J Subst Abuse Treat. 2016; 68:57-61. PMCID: PMC4955948

Wilder CM, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. J Addict Dis. 2016; 35(1):42-51. PMCID: PMC4751580

2015

Bagley SM, Peterson J, Cheng DM, Jose C, Quinn E, O’Connor PG, Walley AY. Overdose education and naloxone rescue kits for family members of individuals who use opioids: Characteristics, motivations, and naloxone use. Subst Abus. 2015; 36(2):149-54. PMCID: PMC4809347

Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence. Drug Alcohol Depend. 2015; 156:70-77. PMCID: PMC4633308

Park TW, Cheng DM, Samet JH, Winter MR, Saitz R. Chronic care management for substance dependence in primary care among patients with co-occurring disorders. Psychiatr Serv. 2015; 66(1):72-9. PMCID: PMC4282827

Tofighi B, Grossman E, Buirkle E, McNeely J, Gourevitch M, Lee JD. Mobile phone use patterns and preferences in safety net office-based buprenorphine patients. J Addict Med. 2015; 9(3):217-21. PMCID: PMC4693598

2014

Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014; 9(1):19. PMCID: PMC4166410

Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014; 109(12):2053-9. PMCID: PMC4229435

Park TW, Bohnert AS, Austin KL, Saitz R, Pizer SD. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy. Psychiatr Serv. 2014; 65(1):4. PMCID: PMC5697151